ELIC.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 06:41):

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden...

Stats
Today's Volume	333 656
Average Volume	80 087.00
Market Cap	20.87M
EPS	SEK-0.255 ( 2023-11-14 )
Next earnings date	( SEK0 ) 2024-05-16
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.270
ATR14	SEK0.0130 (1.23%)

Elicera Therapeutics AB Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Elicera Therapeutics AB Financials

Annual	2023
Revenue:	SEK0
Gross Profit:	SEK-11 776.00 (0.00 %)
EPS:	SEK-0.830

Q4	2023
Revenue:	SEK0
Gross Profit:	SEK-2 938.00 (0.00 %)
EPS:	SEK-0.240

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-2 946.00 (0.00 %)
EPS:	SEK-0.260

Q2	2023
Revenue:	SEK1.77M
Gross Profit:	SEK1.77M (99.83 %)
EPS:	SEK-0.220

Financial Reports:

No articles found.

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio of products in pipeline includes ELC-100, a Phase I/II drug candidate for neuroendocrine tumors indications; ELC-201, a preclinical drug candidate; ELC-301, a CAR T-cell therapy for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a preclinical drug candidate glioblastoma multiforme (brain tumor) indications. It also develops iTANK, a technology platform used to optimize the effect of all CAR T-cell therapies under the development and activate killer T-cells against cancer. The company was founded in 2014 and is based in Göteborg, Sweden.